Kymera Therapeutics (KYMR) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 24, 2026, with shareholders able to vote online or by proxy on key proposals.

• Shareholders of record as of April 27, 2026, are entitled to vote on all matters presented at the meeting.

• The company distributed proxy materials via Internet to reduce costs and environmental impact, with printed copies available upon request.

Voting matters and shareholder proposals

• Four class III directors are nominated for election to serve until the 2029 annual meeting.

• Shareholders will vote on a non-binding advisory resolution to approve executive compensation.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, is on the agenda.

• Shareholders may submit proposals for the 2027 meeting by December 30, 2026, and must follow advance notice procedures for other business.

Board of directors and corporate governance

• The board is divided into three classes with staggered three-year terms; nine directors serve across classes I, II, and III.

• All directors except the CEO are considered independent under Nasdaq and SEC rules.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.

• The chair and CEO roles are separated; Felix J. Baker is expected to become chair after the 2026 meeting.

• The board conducts annual self-assessments and encourages director attendance at meetings.